164931-20-8

Basic information

• Product Name: Benzeneacetic acid, 4-(4-hydroxybutyl)-, methyl ester
• CAS NO: 164931-20-8
• Molecular Formula: C13H18O3
• Molecular Weight: 222.284
• Mol File: 164931-20-8.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: Benzeneacetic acid, 4-(4-hydroxybutyl)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetic acid, 4-(4-hydroxybutyl)-, methyl ester(164931-20-8)
• EPA Substance Registry System: Benzeneacetic acid, 4-(4-hydroxybutyl)-, methyl ester(164931-20-8)

Safety Data

• Hazardous Substances Data: 164931-20-8(Hazardous Substances Data)

Upstream product

• 192804-72-1 methyl 2-(4-(4-hydroxybut-1-yn-1-yl)phenyl)acetate 
• 63349-52-0 methyl 4-iodophenylacetate 
• 1798-06-7 (4-iodophenyl)acetic acid 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 

Downstream Products

• 192804-76-5 methyl 4-(4-iodobutyl)phenylacetate 
• 1579295-39-8 methyl 2-(4-(4-phenylpentyl)phenyl)acetate 
• 1579295-38-7 methyl 2-(4-(4-phenylpent-4-enyl)phenyl)acetate 
• 1579295-37-6 methyl 2-(4-(4,4-difluoro-4-phenylbutyl)phenyl)acetate 
• 1579295-36-5 methyl 2-(4-(4-oxo-4-phenylbutyl)phenyl)acetate 
• 1579295-35-4 methyl 2-(4-(4-fluoro-4-phenylbutyl)phenyl)acetate 
• 1579294-37-3 N-hydroxy-2-(4-(4-hydroxy-4-phenylbutyl)phenyl)acetamide 
• 1579295-34-3 methyl 2-(4-(4-hydroxy-4-phenylbutyl)phenyl)acetate 
• 1579295-33-2 methyl 2-(4-(4-oxobutyl)phenyl)acetate 
• 920525-76-4 methyl 2-(4-(4-(tert-butyldimethylsilanyloxy)-butyl)-phenyl)-acetate 
• 164931-25-3 4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenylacetyl-D-Ser-D-Lys-(2-cyclohexylethyl)amide 
• 1027559-08-5 [(S)-5-[(S)-3-tert-Butoxy-2-(2-{4-[4-(2-isopropyl-imidazol-1-yl)-butyl]-phenyl}-acetylamino)-propionylamino]-5-(2-cyclohexyl-ethylcarbamoyl)-pentyl]-carbamic acid tert-butyl ester 
• 1026688-12-9 [(S)-5-[(S)-3-tert-Butoxy-2-(2-{4-[4-(2-ethyl-imidazol-1-yl)-butyl]-phenyl}-acetylamino)-propionylamino]-5-(2-cyclohexyl-ethylcarbamoyl)-pentyl]-carbamic acid tert-butyl ester 
• 1026034-27-4 [(S)-5-[(S)-3-tert-Butoxy-2-(2-{4-[4-(2-iodo-imidazol-1-yl)-butyl]-phenyl}-acetylamino)-propionylamino]-5-(2-cyclohexyl-ethylcarbamoyl)-pentyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

Nitroxide derivative of ROCK kinase inhibitor

The invention provides a small molecular compound of a NO donor. The small molecular compound is characterized in that the small molecular compound is a compound shown represented by structural formula I shown in the description, or a stereoisomer, a geometrical isomer, a tautomer, a racemate, a deuterated isotope derivative, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof; and in the formula I, ring A is a substituted or unsubstituted heteroaromatic ring, X is selected from (CH2)n, n is selected from 0, 1, 2 and 3, R is a substituent group of terminal -O-NO2, R is selected from hydrogen, a hydroxyl group, halogen, an amino group, a cyano group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group and a substituted or unsubstituted heteroalkyl group, and R and R are respectively and independently selected from hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted naphthenic base or an amino protecting group, or R and R are connected to form a substituted or unsubstituted cyclic heteroalkyl group. The compound has a high-activity inhibition effect on ROCK kinase.

ARYLTHIAZOLIDINEDIONE DERIVATIVES

Substituted 5-aryl-2,4-thiazolidinediones are potent agonists of PPAR, and are therefore useful in the treatment, control or prevention of diabetes, hyperglycemia, hyperlipidemia (including hypercholesterolemia and hypertriglyceridemia), atherosclerosis, obesity, vascular restenosis, and other PPAR alpha , delta and/or gamma mediated diseases, disorders and conditions.

COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY

This invention provides compounds of formula I wherein R1, R2, R3, R4, R5, R6, R7, R8a, R8b, W, a and b are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Accordingly, such compounds are expected to be useful as therapeutic agents for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.